BridgeBio Pharma, Inc.BBIO
| Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Cash and cash equivalents | 364 | 356 | 394 | 377 | 376 | 681 |
|---|
| Marketable securities | 182 | 251 | 394 | 52 | - | - |
|---|
| Investments in equity securities | - | - | 49 | 44 | 59 | - |
|---|
| Accounts receivable | - | - | - | - | - | 5 |
|---|
| Receivables, Long-Term Contracts or Programs | - | - | 20 | 17 | 2 | - |
|---|
| Restricted cash | - | - | - | 38 | 17 | 0 |
|---|
| Prepaid expenses and other current assets | 23 | 36 | 32 | 22 | 24 | 35 |
|---|
| Total current assets | 569 | 643 | 889 | 549 | 478 | 721 |
|---|
| Investment in nonconsolidated entities | - | - | - | - | - | 144 |
|---|
| Property and equipment, net | 6 | 20 | 30 | 15 | 12 | 7 |
|---|
| Operating lease right-of-use assets | - | 17 | 16 | 11 | 8 | 6 |
|---|
| Intangible assets, net | - | - | 45 | 29 | 26 | 24 |
|---|
| Other assets | 26 | 24 | 33 | 20 | 23 | 18 |
|---|
| Total assets | 632 | 704 | 1,013 | 623 | 546 | 919 |
|---|
| Accounts payable | 9 | 9 | 12 | 12 | 11 | 10 |
|---|
| Accrued compensation and benefits | 13 | 30 | 37 | 31 | 57 | 58 |
|---|
| Accrued research and development liabilities | 21 | 27 | 44 | 40 | 30 | 34 |
|---|
| Operating Lease, Liability, Current | - | 4 | 5 | 4 | 4 | 5 |
|---|
| Deferred Revenue, Current | - | - | - | 8 | 6 | 15 |
|---|
| Accrued professional and other accrued liabilities | - | - | - | - | 36 | 33 |
|---|
| Total current liabilities | 60 | 96 | 135 | 121 | 144 | 154 |
|---|
| 2029 Notes | - | - | 733 | 735 | 737 | 739 |
|---|
| 2027 Notes | - | - | 540 | 542 | 543 | 545 |
|---|
| Notes, net | - | 383 | - | - | - | - |
|---|
| 2029 Notes | - | - | 733 | - | - | - |
|---|
| 2027 Notes | - | 383 | 540 | - | - | - |
|---|
| Term loan, net | 92 | 92 | 431 | 431 | 446 | 437 |
|---|
| Deferred royalty obligation, net | - | - | - | - | - | 479 |
|---|
| Operating Lease, Liability, Noncurrent | - | 15 | 17 | 12 | 9 | 5 |
|---|
| Deferred Revenue, Noncurrent | - | - | - | - | - | 17 |
|---|
| Other long-term liabilities | 4 | 10 | 22 | 27 | 9 | 0 |
|---|
| Total liabilities | 156 | 596 | 1,878 | 1,868 | 1,889 | 2,377 |
|---|
| Redeemable convertible noncontrolling interests | - | - | - | -2 | 0 | 0 |
|---|
| Common Stock, Value, Issued | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Treasury stock, at cost; 6,191,761 shares as of December 31, 2024 and December 31, 2023 | - | 75 | 275 | 275 | 275 | 275 |
|---|
| Additional paid-in capital | 848 | 1,021 | 842 | 939 | 1,481 | 1,903 |
|---|
| Accumulated other comprehensive income | 0 | 0 | -0 | -0 | 0 | 0 |
|---|
| Accumulated deficit | -440 | -889 | -1,437 | -1,918 | -2,561 | -3,096 |
|---|
| Total BridgeBio stockholders' deficit | 474 | 106 | -867 | -1,243 | -1,343 | -1,458 |
|---|
| Noncontrolling interests | 65 | 48 | 3 | 11 | 11 | 10 |
|---|
| Total stockholders' deficit | 474 | 106 | -867 | -1,243 | -1,343 | -1,458 |
|---|
| Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit | 632 | 704 | 1,013 | 623 | 546 | 919 |
|---|